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This systematic review summarizes the prevalence of treatment-emergent central sleep apnea (TECSA)
occurring with therapies other than positive airway pressure (PAP) for the management of obstructive
sleep apnea (OSA). We describe its natural course as well as the proposed underlying pathophysiological
mechanisms and the clinical management of affected patients. A systematic search of PubMed, Embase,
Web of science, and the Cochrane Library was performed until June 2020. Eighteen studies (n ¼ 284
patients) were included. TECSAwas observed in 31 patients with the use of four different medical devices
(mandibular advancement device, hypoglossal nerve stimulation, tongue stabilizing device and nasal
expiratory PAP) and after three different types of surgical treatments (tracheostomy, maxillofacial sur-
gery and oro-nasal surgery). Due to the paucity of data available, it was not possible to establish a clear
prevalence rate of TECSA for each alternative treatment. After the initiation of non-PAP treatments, a
systematic reassessment of the treatment efficacy with follow-up sleep studies will be helpful to identify
TECSA. A spontaneous resolution over time was described as well as a persistence of TECSA. In this case,
treatment should focus on patients’ specific underlying pathophysiology. Overall, the limited current
literature suggests that this phenomenon is rare (<4%).
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Treatment-emergent central sleep apnea (TECSA) is a well-
known phenomenon occurring in obstructive sleep apnea (OSA)
patients upon application of positive airway pressure (PAP). In the
largest study so far, the prevalencewas 6.5% for CPAP-related TECSA
[1]. A literature review confirmed this data with an aggregate
prevalence of 8% [2], but also showed that prevalence may vary
from 1.6% to 20.3% [3,4] depending on the applied inclusion criteria
for comorbidities, titration protocols, and geographical settings.
Usually, TECSA is characterized by persistence or emergence of
central apneas on exposure to PAP devices without a backup rate
while the obstructive respiratory events that were noted during thee Recherche sur le Sommeil
V), Rue de Bugnon 46, 1011,
er).
r Ltd. This is an open access articleprior diagnostic sleep study have resolved. In addition, central sleep
apnea (CSA) should not be better explained by another disorder
causing CSA syndrome.
Already in the 1980s, a PAP-independent nature of TECSA has
been observed after tracheostomy in patients with severe OSA or
“hypersomnia sleep apnea” as the disease was still called at that
time [5,6]. With the subsequent great success of continuous posi-
tive airway pressure (CPAP) as first line treatment for OSA, research
and reports on TECSA initially focused on this treatment modality
and in 2014 TECSA was officially incorporated in the International
Classification of Sleep Disorders e Third edition (ICSD-3) [7].
Althoughmentioned in the ICSD-3 chapter on TECSA, the definition
does not include the occurrence of central apneas in OSA patients
when restoring upper airway patency using other treatment mo-
dalities. Yet, alternative treatment modalities to CPAP are increas-
ingly used in clinical practice and first reports on TECSA occurring
with the use of devices such as mandibular advancement devices




CAI Central apnea index
CMAI Central and mixed apnea index
CPAP Continuous positive airway pressure
CSR Cheyne-Stokes respiration
HNS Hypoglossal nerve stimulator
ICSD-3 International Classification of Sleep Disorders e
Third edition
MAD Mandibular advancement device
MeSH Medical subject headings
MMA Maxillomandibular advancement
NOS NewcastleeOttawa Scale
OSA Obstructive sleep apnea
PAP Positive airway pressure
PSG Polysomnography
TECSA Treatment-emergent central sleep apnea
TPCSA Treatment persistent central sleep apnea
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ment modalities remains largely unknown.
With this systematic review, we aimed to investigate the prev-
alence of TECSA occurring with alternative therapies to PAP for the
treatment of OSA and to describe its natural course as well as the
underlying pathophysiological mechanisms and the clinical man-
agement of affected patients.
Methods
This systematic review was prospectively registered in PROS-
PERO (CRD42020149067).
Identification of studies
A systematic search of electronic databases including PubMed,
Embase, Web of science, and the Cochrane Library was performed
from inception through August 29, 2019. An update search was
performed on June 30, 2020. The search included MeSH terms,
keywords and phrases in various combinations. The following
syntax was used as search strategy in the different electronic da-
tabases ([“Sleep Apnea, Central” (MeSH)] AND [treatment-
emergent) OR (treatment) OR (emergent”) OR (complex)]. In
addition, we performed backward and forward citation-chaining of
relevant literature from the reference lists of identified reports and
articles to identify other pertinent articles that might have been
missed during the electronic database search. No language limits
were imposed at the time of screening the articles. Selection of
relevant studies was performed in duplicate by at least two inde-
pendent investigators using Covidence tool [10] and any disagree-
ment was resolved by consensus with a third reviewer.
Inclusion and exclusion criteria
The inclusion criteria were the following: 1) human participants
of both sex; 2) participants aged 16 years or older; 3) OSA assessed
by polysomnography (PSG) or respiratory polygraphy at baseline;
4) treatment with another treatment modality than PAP (e.g., sur-
gery, other devices); 5) a new or established diagnosis of TECSA
with this alternative treatment by PSG or polygraphy without time2
restrictions. We included reports fulfilling the ICSD-3 TECSA defi-
nition and those with TECSA defined close to this definition only if
they provided enough data to allow comparison to the other
studies. Missing subclassification of hypopneas as obstructive or
central were tolerated.
Articles were excluded if 1) patients did not receive any treat-
ment for OSA; 2) there was no detailed information on the alter-
native treatment; 3) there was no detailed description of the
follow-up.Data extraction and management
Data extraction was performed in duplicate (MB and AKB) from
all eligible studies with a standardized pre-specified data collection
sheet. The following aggregate data were collected: first author's
name, year of publication, number of participants, gender, age,
body mass index (BMI), comorbidities, apnea-hypopnea index
(AHI) at baseline and at follow-up, central apnea index (CAI) at
baseline and at follow-up, prior OSA treatment if any, type of
treatment that led to TECSA, symptoms with non-PAP treatment,
frequency of TECSA, time and number of follow-up visit, delay until
onset of TECSA, further evolution, and applied countermeasures.
Any disagreements between the investigators were resolved by
research team consensus.Quality assessment
For the included cohort studies we applied the New-
castleeOttawa Scale (NOS) [11]. Given that there are still no vali-
dated tools to assess the risk of bias of case reports and case series,
we utilized an adapted form of the NOS with items that were
appropriate for this systematic review [12]. In the adapted version
NOS items that related to comparability and adjustment were
removed and those that focused on selection, representativeness of
cases, and ascertainment of outcome and exposure were retained.
This resulted in five criteria in the form of questions with a binary
response (yes/no), whether the item was suggestive of bias or not.
The quality of the report was considered as good (low risk of bias)
when all five criteria were fulfilled, as moderate when four criteria
were fulfilled and poor (high risk of bias) when three or fewer were
fulfilled. Disagreement between the reviewers was resolved
through research team consensus.Results
Study selection
The schematic presentation of the study selection using the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines is depicted in Fig. 1:
(i.) Identification: A total of 982 studies were generated from the
database searches (Pubmed: 419 studies, Embase: 385 studies, Web
of Science: 156 studies, and Cochrane Library: 22 studies), and
additional seven were retrieved from backward and forward
searching of reference lists of relevant articles and the final studies
(ii.) Screening: after removal of duplicates 729 titles and abstracts
were screened for eligibility; 692 did not meet basic eligibility
criteria including one study without any abstract or full-text
available [13] (iii.) Eligibility: 37 full-text articles were retrieved
and further screened for eligibility. Nineteen studies were excluded
for different reasons (iv.) Included: Eighteen studies were included
in the present systematic review.
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Fig. 1. Flow diagram of the literature search and study selection process.
M. Berger, G. Solelhac, C. Horvath et al. Sleep Medicine Reviews 58 (2021) 101513Study characteristics
A summary of the included studies and applied treatment mo-
dalities is presented in Tables 1 and 2. The included studies were
one prospective and one retrospective cohort, two case series, and
14 case studies comprising overall 284 patients, 31 out of themwith
TECSA. Studies included mostly men, middle-to-older-age patients
who were overweight or obese. The majority of reports stems from
sleep centers in North America (USA: 14 studies, Canada: two
studies, France: one study, Italy: one study).
TECSA was described with the use of four different medical
devices (MAD in four studies, hypoglossus nerve stimulator (HNS)
in four studies, tongue stabilizing device and nasal expiratory PAP
(nEPAP) in one study each, and after three different types of surgical
treatments (tracheostomy in three studies, maxillofacial surgery in
two studies and oro-nasal surgery in three studies). The risk of bias
in the included case reports and case series was moderate or low
(Table 3). The quality of the cohort studies was considered fair [14]
or good [15].
Mandibular advancement devices
Our search identified four detailed publications comprising five
male patients with OSA who developed TECSA with the use of a
MAD (Table 1). Thus, no prevalence data was available for this
treatment modality. The described patients had a mean age of 53.4
years (range 32e69) and a mean BMI of 31 kg/m2. Comorbidities3
were variable but included atrial fibrillation in combination with
arterial hypertension or a structural cardiac disease in all but the
youngest patient. Left ventricular ejection fraction was reported as
preserved in three patients. Medication included treatments for the
comorbidities, but no drugs known to provoke CSA. TheMADswere
rigid bi-bloc devices in four cases and a soft mono-bloc device in
one patient. Baseline OSA diagnostics showed a wide AHI range in
the patients (ranging from 10.1 to 65 events/h) and an increase in
the CAI with TECSA that fulfill the ICSD-3 definition for TECSA in all
described cases. The interval between the start of the treatment
with the MAD and the diagnosis of TECSAwas not always described
in detail. In three cases, the follow-up PSG revealing TECSA was
performed two or three months after the initiation of the MAD
treatment [8,9,16]. Despite the development of TECSA, two patients
reported an improvement in symptoms, while there was no change
in excessive daytime sleepiness in two other patients. The under-
lying mechanisms as proposed by the authors varied and included
insufficient mandibular protrusion leading to persistent micro-
arousals destabilizing nocturnal breathing [8], excessive mandib-
ular protrusion [9], or high loop gain [17]. Noteworthy, a
physiological spontaneous resolutionwas frequently observed over
time [16].
This resulted in heterogeneous and individualized further
treatment decisions ranging from the continuation of the MAD
with a wait and see strategy and no change in the treatment, to a
continued MAD use with an altered level of protrusion, alternating
the MADwith CPAP, or a change to adaptive servoventilation (ASV).
Table 1


















Symptoms with TECSA Further management

















1 n/a 1 (100%) 28 50 Afib, Hypothyreosis
UPPP
27 6 mm: 19
9 mm: 52
0 6 mm: 2
9 mm: 34
6 mm: snoring Y,
unchanged EDS,
9 mm: snoring Y,
unchanged EDS
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EDS (ESS 19 / 13)
Persistent EDS/fatigue












1 n/a 1 (100%) 36.5 69 Afib, HTN, CAD, DM 16.2 14.9 0 7.3 Fatigue/poor sleep
quality resolved
Spontaneous resolution
PSG after 15 months

















1 n/a 1 (100%) 27 60 AH, CKD, DM,
bladder/kidney
cancer, depression
22.6 83.8 0.3 78.9 þ CSR Improved EDS (ESS
11 / 7) and nocturnal
breathing
HNS continued, repeat







1 n/a 1 (100%) NR 76 Afib 18.6 NR 0.7 CSR NR HNS continued þ Afib









3.3% 94 (66.9%) 29.1 ± 3.9 61 ± 11 CCI  2 in 69% of
patients








Transient (n ¼ 3), resolution
with adapted HNS
configuration (n ¼ 1),








Case study 1 n/a 1 (100%) 24 72 mitral valve prolapse,
septal deviation












Case study 1 n/a 1 (100%) NR 70 DM, AT, CAD,
depression, lat. TBC,
NHL, hypercalcemia




Abbreviations: AMP™: anterior mandibular positioning device; AFib: atrial fibrillation; BiPAP: bilevel positive airway pressure; BL: baseline; CAD: coronary arterial disease; CCI: Charleston comorbidity index; CKD: chronic
kidney failure; CMAI: central and mixed apnea index; CPAP: continuous positive Airway pressure; CSR: Cheyne-Stokes respiration; DeSRA®: Dental Sleep Relief Appliance; DM: diabetes mellitus; EDS: Excessive daytime
sleepiness; ESS: Epworth sleepiness scale; FU: follow-up; nEPAP: nasal end expiratory positive airway pressure; HNS: hypoglossus nerve stimulator; HTN: hypertension; MAD: mandibular advancement device; NHL: non
Hodgkin lymphoma; NR¼ not reported; n/a ¼ not applicable; pat: patient; REI: respiratory event index; lat. TBC: latent tuberculosis; UPPP: uvulopalatopharyngoplasty; *CAI >5/h [-]: range; y: years; n/h: number of events per

















Characteristics of the included studies with surgeries.
Author,
reference





























1.8%* 84 (74%) NR 44 ± 9
[17e68]















Nasal surgery Case study 1 n/a 1 (100%) 31.2 43 Sino-nasal
congestion

























Tracheostomy Case series 10/5
TECSA













65 ± 14 d2-3: 13 ± 3
w4-5: 7 ± 1
m3: 2 ± 2
1.1 d2-3: 30 ± 5







Tracheostomy Case study 1 n/a 1 (100%) Super-
obese








Abbreviations: NR¼ not reported, n/a¼ not applicable, ENT: Ear nose throat, EDS: Excessive daytime sleepiness, * CAI > 5/h, HTN: hypertension; BL: baseline; NIV: non-invasive ventilation; FU: follow-up; y: years; n/h: number

















Risk of bias of the included case studies and case series.
First author, year Q1 Q2 Q3 Q4 Q5 Risk of bias
Yes No Yes No Yes No Yes No Yes No
Tongue stabilizing device
Alshhrani, 2019 [21] x x x x x moderate
Mandibular advancement device
Avidan, 2006 [8] x x x x x moderate
Gindre, 2006 [9] x x x x x moderate
Kuzniar, 2011 [17] x x x x x low
Mohan, 2016 [16] x x x x x low
Nasal expiratory positive airway pressure
Chopra, 2014 [22] x x x x x low
Hypoglossus nerve stimulator
Chan, 2018 [18] x x x x x low
Hong, 2019 [20] x x x x x low
Sarber, 2019 [19] x x x x x moderate
Tracheostomy
Weitzmann, 1980 [5] x x x x x moderate
Guilleminault, 1982 [6] x x x x x moderate
Fletcher, 1989 [23] x x x x x moderate
Maxillofacial surgery
Corcoran, 2009 [24] x x x x x low
Other upper airway surgery
Goldstein, 2012 [26] x x x x x low
Qamer, 2015 [27] x x x x x low
Testani, 2018 [25] x x x x x moderate
Total: 16 studies Low risk: 8
Moderate risk: 8
High risk: 0
Detailed questions of the adapted Newcastle Ottawa scale: Q1. Did the patient(s) represent the whole case(s) of the medical center? Q2. Was the diagnosis correctly made?
Q3.Were other important diagnoses excluded? Q4. Were all important data cited in the report? Q5. Was the outcome correctly assessed?
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The four identified reports from the USA included a prospective
cohort study with 141 patients and three case reports on patients
who developed TECSA with the use of an HNS (Table 2). The
prevalence of TECSA in the monocentric prospective cohort was
reported as 3.3% (n¼ 5 patients) [15]. The authors defined TECSA as
patients with OSA (with a baseline CAI < 5 events/h) who
demonstrated a central and mixed apnea index (CMAI) of 5
events/h and/or demonstrated Cheyne-Stokes respiration (CSR)
becoming prominent or disruptive on HNS treatment, measured
during the therapeutic device titration 6e8 weeks after device
activation. As detailed data were reported mainly for the whole
cohort, there is no full individual information available on patients
who developed TECSA, but the authors reported a trend towards a
lower BMI in affected patients. The Charlson Comorbidity index
was 2 in 69% of all studied patients but details on the comor-
bidities, such as possible heart failure were not reported. All
affected patients with an elevated CMAI after HNS activation were
male and univariate analysis revealed that demographics, comorbid
conditions, and device settings were not associated with an
elevated postoperative CMAI. The only factor associated with CMAI
5 events/h on univariate analysis was an elevated postoperative
AHI.
In the three case studies, all patients were male, aged between
60 and 76 years and two had comorbidities including chronic
kidney disease, cardiac disease and atrial fibrillation [18e20]. Pol-
ysomnographies revealing TECSA were performed two to three
months after the device implantation.
Pathophysiological considerations of the authors mainly
focused on either an unresolved obstructionwhich may have led to
microarousals and overshoot of PaCO2 reduction below the apneic
threshold during sleep or a demasking of an OSA or comorbidity
related elevated loop gain. HNS was continued either with spon-
taneous resolution of central and mixed events over time or with6
advanced programming of the HNS device. In addition, the authors
recommended a good control of co-morbidities including ablation
of atrial fibrillation, and considered supplemental oxygen or the
prescription of acetazolamide or eszopiclone. Only one of the eight
affected patients had to discontinue HNS and was started on bilevel
positive airway pressure therapy (BiPAP).Other devices
One case report by Alshhrani et al. described TECSAwith the use
of a tongue protrusion device (aveoTSD®, Innovative Health Tech-
nologies, New Zeeland) in a male OSA patient with several
comorbidities including coronary artery disease [21]. After an
initially good response to the treatment with the tongue protrusion
device, a split-night sleep study performed eight months later as
part of a research trial revealed an insufficient control of sleep
apnea with TECSA in the second half of the night with the device
(Table 1). Although occurring in both supine and non-supine po-
sition, TECSA was more profound in the supine position, indepen-
dently of sleep-stage effects. The patient's medications andmedical
conditions did not change during the follow-up. The authors did
not bring forward any potential pathophysiological mechanisms.
Another case of TECSA was reported with a Provent® nEPAP
device occurring in an elderly male patient with moderate OSA
during a split-night PSG [22]. The patient had a cardiac dysfunction,
a normal BMI and presented mixed (17/h) and central apnea events
(11/h) with nEPAP in the second half of the night. Surprisingly,
there was more REM sleep in the second half of the split-night
(19.2% vs 2.6% in the first part of the diagnostic split night),
which actually should have decreased the likelihood of CSA. The
patient declined treatment and was not seen until 1 y after the
sleep study. Then, CPAP was tried resulting in a CAI of 5 events/h,
but also declined by the patient who was then advices to utilize
positional therapy.
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Three studies describing the occurrence of TECSA after trache-
ostomy were identified (Table 2). Since the case studies included
only 16 patients, no real prevalence data was available.
Weitzmann et al. describe a homogeneous group of ten severe
OSA patients with available PSG data acquired shortly after the
tracheostomy (n ¼ 9 in night 5, n ¼ 1 in night 41) [5]. In parallel
with a reduction of obstructive apnea events, seven patients pre-
sented a small increase of CAI, five of them with a post-
tracheostomy CAI of more than 5 events/h meeting the definition
of TECSA. The length of the central apneas was unchanged after
tracheostomy compared to baseline.
A second case series by Guilleminault and Cummiskey described
a progressive improvement of the apnea index after tracheostomy
with a transient increase in CAI [6]. Patients underwent at least
three follow-up PSGs showing a greatly increased CAI immediately
after surgery, remaining elevated during four to five weeks post-
surgery and then progressively normalizing over time while
obstructive apneas remained low from the first postsurgical
recording onwards.
The case report from 1989 by Fletcher describes a different type
of TECSA [23]. With further weight gain, a male superobese OSA
patient developed hypercapnic CSA and right heart failure with
edema 4 years after tracheostomy. TECSA was reversed by a tem-
porary application of mechanical ventilation over the tracheostomy
and edema was treated with diuretics. Pathophysiological consid-
erations by the author focus on alveolar hypoventilation induced by
morbid obesity with chronic hypercarbia and hypoxemia predis-
posing to periodic breathing during sleep through changes in the
respiratory controller.Maxillofacial surgery
The emergence of TECSA after maxillofacial surgery was
analyzed in a larger retrospective cohort including 113 patients
as well as in a single case report. In the cohort study, PSGs were
performed before maxillomandibular advancement (MMA) sur-
gery and six months afterwards. Thirty-four patients of 73 (46%)
without any central apneas before surgery experienced very mild
and clinically insignificant new-onset central apneic events with
a CAI range of 0.3e3 events/h and only one patient had a CAI of
>5 events/h [14]. Of the 40 patients who presented with a few
central apneic events before surgery, 39 experienced a decrease
in their CAI from a mean CAI of 1.79 to 0.75 events/h, all having a
CAI <5 events/h. Only one patient showed an increase in CAI
from 0.2 to 11.2 events/h with a CSR pattern. This resulted in a
TECSA prevalence of 1.8% in this cohort. The authors did not find
any correlation of the postoperative development of central
apneic events with male gender, patient age or increased pre-
treatment AHI [14].
The case study from Corcoran et al. reported a more severe
development of TECSA in a younger man that was evident in a PSG
performed three months after MMA surgery [24]. The post-surgery
CAI was 35 events/h and normalized spontaneously to 1.9 events/h
in the follow-up PSG six months after the surgery. No information
on sleeping position during the PSG was available. Despite being
slightly overweight, the patient had no comorbidities. Pathophys-
iological aspects discussed by the authors focused on high loop
gain, potential atmospheric glottis closing pressure with adaption
of the ventilatory control to the new anatomical situation and
reduced ventilatory load over time [24]. They proposed to wait at
least six months after surgery before performing postoperative
PSG.7
Other surgery
The case study described by Testani et al. nicely documented the
course of an early and transient TECSA in an otherwise healthy OSA
patient who was moderately hypercapnic before upper-airway
surgery including mucotomy, uvulopalatopharyngoplasty (UPPP)
and partial epiglottectomy [25]. A series of PSGs performed three,
15 and 30 days after this surgery documented an early CAI increase
that spontaneously and progressively decreased over time. The
authors ruled out medication, neurologic, heart and respiratory
disease. Therefore, they suggested TECSA to be triggered by a
sudden normalization of nocturnal pCO2 immediately after surgery
in a patient with reduced chemosensitivity due to a long-term
exposure to nocturnal hypercapnia. Another case study described
TECSA after a nasal surgery for a mild OSA that was detected due to
worsening symptoms with sleepiness and sleep fragmentation
[26]. In this case, the authors noted an increase of RERAs in the
follow-up PSG indicating a mixed pattern of insufficient relief of
OSA and emergence of CSAwith the surgery. Time in each sleeping
position was not indicated in the initial diagnostic study, but the
patient had position dependent sleep apnea in both PSGs. The au-
thors discuss an increase in upper airway resistance and arousals as
potential underlying mechanisms that contribute to ventilatory
instability [26]. A similar case was presented in an abstract with
TECSA being diagnosed about four months after UPPP, tonsillec-
tomy and partial resection of the inferior turbinates bilaterally.
TECSA also consisted of a mixed pattern of respiratory events with
persistent obstructive hypopneas, but the majority of apneas and
>50% of the AHI being central. Pathophysiological considerations of
the authors focus on an augmented response to pCO2 and persis-
tence of OSA, but the authors also indicate that the baseline and
follow-up PSGs were performed at different institutions implying
potential technical and interpretative differences [27].
Discussion
This systematic literature review is the first, to our knowledge, to
investigate the prevalence and the pathophysiological mechanisms
of TECSA with non-PAP therapies across several different treatment
modalities. Eighteen studies were included that addressed TECSA
occurring with four different medical devices (MAD, HNS, tongue
stabilizing device and nEPAP), and three different types of surgical
treatments (tracheostomy, maxillofacial surgery and oro-nasal sur-
gery) to treat OSA. Although rare, our findings highlight that TECSA
may occur with almost all common alternative treatment modalities
and with heterogeneous pathophysiological mechanisms. Given the
number of case reports and small case series included in this review,
the true prevalence and clinical relevance of this phenomenon is still
difficult to assess due to insufficient data for most treatment
modalities.
Prevalence of TECSA with non-PAP therapies
The two cohort studies reported a 3.3% and 1.8% prevalence rate
for HNS andmaxillofacial surgery, respectively [14,15]. Surprisingly,
while oral appliances are currently the most common alternative
treatment for OSA management [28,29], we did not identify any
cohort studies establishing a prevalence rate of TECSA with this
kind of treatment. Still, the four identified case reports suggest that
TECSA with MAD may occur. The prevalence rates for TECSA with
HNS or after MMA surgery are lower than the prevalence reported
with PAP therapy in the largest CPAP-study (6.5%) [1] and the
systematic review of first time PAP-users (prevalence 8%, range
5.0e20.3% with 5.0e12.1% for full-night PSG and 6.5e20.3% for
split-night PSG) [2]. A potential explanation for the observed
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longer interval with non-PAP treatments between the start of the
intervention and follow-up diagnostic. Indeed, in-laboratory fixed
pressure PAP titration will immediately reveal PAP-related TECSA.
Similarly, PAP initiation in an outpatient setting with auto-CPAP
devices provides a night-by-night analysis of residual events and
may revealed PAP-related TECSA almost in real-time via tele-
monitoring [30].
By contrast, the PSGs after MMA or HNS were performed six
months after surgery or six to eight weeks after the device acti-
vation, respectively. Therefore, with the exceptions of the few pa-
tients who were evaluated immediately after the initiation of a
treatment, it seems more reasonable to compare TECSA induced by
non-PAP alternatives to OSA patients who experience CSAwith PAP
over a prolonged period of time, i.e., treatment persistent central
sleep apnea (TPCSA). Of interest, the prevalence data for PAP
associated TPCSA on a long-term basis was 1.5% in the large CPAP-
study [1] and ranged from 0.9 to 3.2% in a recent review [31] and
although the authors consider this number to be potentially
underestimated, it is closer to the prevalence data that we found for
the cohort studies on HNS and MMA.
In our opinion, a potential underreporting of non-PAP related
TECSA also warrants consideration as potential explanation for the
scarce literature and low prevalence obtained, particularly with
MADs as the most common second line treatment for OSA. One
may argue that, although recommended, OSA is not always sys-
tematically re-assessed with a sleep study after the initiation of an
alternative medical device or surgical treatment [29], as follow-up
may only be symptom based and up to 20e25% of the patients do
not keep regular appointments [32]. Limited resources to follow-up
increasing numbers of OSA patients [33] by sleep centers [34] and
the lack of device-generated data or telemonitoring options for
most of the non-PAP alternatives also reduce the likelihood of a
detection of TECSA.
Other potential explanations for a truly low prevalence of TECSA
with the non-PAP alternatives compared to CPAP lay in the different
pathophysiological mechanisms between the treatment modalities
themselves. For instance, PAP-related TECSA may be promoted by
an exaggerated CO2 washout and activation of lung stretch re-
ceptors by increased tidal volumes that will inhibit the central
respiratory motor output via Hering Breuer reflex [35]. These latter
two mechanisms cannot be induced by the alternative treatment
modalities. In addition, one could argue that there is a selection bias
since patients receiving non-PAP treatment alternatives might have
a lower AHI, a lower degree of comorbidities, and possibly a lower
fraction of central apneas as compared to patients who receive
CPAP.Natural course
Since most of the studies included in the present systematic
review were case reports or small case series, the timing of TECSA
diagnostic could vary from few days up to several months after
treatment initiation. Moreover, TECSA was not systematically re-
assessed in the studies that we identified. Thus, it is difficult to
characterize the natural evolution of TECSA for each non-PAP
treatment. Nevertheless, a spontaneous resolution of early TECSA
was nicely illustrated in several publications. This was notably the
case over a period of several months in one case series after tra-
cheostomy [6], after maxillofacial surgery [24] as well as in another
case report over a period of 30 days after a complex ear-nose throat
surgery [25]. Similar spontaneous resolution was found in some
patients with HNS [15] or MAD [16]. However, these spontaneous
resolutions are not systematic and other authors reported some8
cases with persistence of CSA over time [15]. Moreover, some au-
thors proposed an immediate change of the treatment modality or
a change of configuration of the device once TECSA is diagnosed,
precluding to determine the natural course of TECSA with the non-
PAP therapy.
Underlying pathophysiological mechanisms
The main pathophysiological mechanism of TECSA is certainly
the dysregulated chemoreflex response to PaCO2 of OSA patients
newly treated. This mechanism was previously demonstrated with
PAP-treatments and results showed that the ventilatory control
adapts and normalizes within a period of a few weeks to several
months [31,36,37]. Even though not all 31 retrieved TECSA cases in
this review were thoroughly classified by the authors, we suggest
that this mechanism also occurs with alternative treatments in
susceptible patients, especially if reassessed early after the imple-
mentation of the alternative OSA treatment modality. In addition,
some patients may suffer from comorbidities that favor an elevated
loop gain, which consequently could favor TECSA once inspiratory
flow limitation is relieved. Similarly, dynamic loop gain is elevated
in supine position due to decreased supine lung volume [38] and
thus may increase the likelihood of CSA in the follow-up studies if
this body position is then preferred. However, only a few of the
identified studies report body position during the sleep studies,
thus we cannot confirm this hypothesis, but clinicians should
consider the body position when TECSA is diagnosed.
In this review, we noted that several patients in the case studies
suffered from cardiac comorbidities, including atrial fibrillation.
Though this was not systematically assessed in the retrieved
studies, it has been suggested as a risk factor for PAP-associated
TECSA by some authors [39,40].
Another hypothesis for TECSA includes insufficient treated up-
per airway obstruction. For instance, Avidan showed that MAD ef-
ficacy could not be reached after several months of therapy [8] and,
in response, Guilleminault and Robinson speculate that the
advancement was not big enough and may lead to microarousals
[41]. Similar mechanisms were found with HNS [18] and also after
surgeries residual upper airway obstruction was speculated to
promote TECSA [26,27]. By contrast, one study discussed a too far
advancement of an MAD as a potential cause for TECSA, which
might be triggered by discomfort and thus sleep instability [9]. Of
note, medication that might predispose to CSA was assessed by all
authors of the included studies and probably not involved in the
affected patients.
Clinical management
Given the likelihood of a spontaneous resolution of TECSA, it
seems reasonable to allow some time between treatment initiation
and a follow-up sleep study. Our systematic review did not reveal
evident subjective symptoms associated with TECSA, even though
individual cases reported persistent EDS. This is quite similar to
PAP-associated TECSA that may occur with typical symptoms for
sleep disordered breathing but may also be asymptomatic in some
patients [30]. We can thus wonder if asymptomatic patients need a
specific treatment or not, especially if residual AHI and ODI are mild
or moderate. Therefore, patients that report an improvement in
OSA symptoms may be reassured and an objective reassessment of
treatment efficacy can be performed after three to six months after
treatment initiation to allow some time for the ventilatory control
to adapt. Those who still complain about sleepiness should be
reassessed earlier with a sleep study to differentiate between
remaining residual upper-airway obstruction or TECSA. Physicians
Practice Points
1) The prevalence of TECSA is 1.8% in maxillomandibular
advancement surgery and 3.3% with hypoglossal nerve
stimulation according to two cohort studies.
2) Although probably rare, clinicians have to be aware that
treatment-emergent central sleep apnea may also occur
with alternative treatments such as mandibular
advancement devices, tracheostomy or upper airway
surgery.
3) A systematic reassessment of the treatment efficacy with
follow-up sleep studies will help to identify TECSA, but
should be scheduled in an appropriate timely manner,
e.g., after three to six months after treatment initiation in
asymptomatic patients as TECSA may resolve
spontaneously.
4) If TECSA occurs, the underlying pathophysiology and




1) Assess the true prevalence and relevance of TECSA in
larger cohorts with alternative treatments to CPAP,
especially with the frequently used mandibular
advancement devices.
2) Determine the underlying pathophysiological mecha-
nisms as well as patient and treatment related risk factors.
3) Determine the implication of TECSA on long-term
adherence to non-PAP device treatments.
4) Assess which central apnea index threshold may be
relevant and translate into cardiovascular risks.
5) Determine the consequences of TECSA on long-term
outcome and residual symptoms.
* The most important references are denoted by an asterisk.
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terventions such as an increase or decrease in MAD protrusion, or
advanced programming of an HNS including electrode configura-
tion, stimulation amplitude, and pulse width and rate. Meanwhile,
underlying comorbidities should be investigated and treated, if
possible (e.g., kidney failure, heart failure, opioids). For treatments
that involve surgery, it is important to wait for a healing of the
surgical sites. Otherwise, swelling may not yet allow a sufficient
relief of upper airway obstruction and pain as well as a still exag-
gerated CO2 response may promote CSA.
Even though TECSA may resolve spontaneously, the decision to
wait may be difficult in some patients. This is particularly true for
those who continue to be symptomatic, those who work as pro-
fessional driver, or those who present prolonged or very deep
desaturations. Thus, combining the current treatment with other
modalities, such as sleep position treatment, CPAP or adaptive
servoventilation may be considered on an individual basis. Addi-
tion of acetazolamide or sleep stabilizing medication such as traz-
odone for example might be considered, but currently there are no
studies to support the efficacy of these interventions in non-PAP
related TECSA.
More generally, we believe that it is important to reassess sys-
tematically and objectively the efficacy of the OSA treatment to
assure that those TECSA patients who might benefit from earlier
interventions will not be missed. Standardized follow-up could
facilitate this in clinical practice for non-PAP treatments and will
also allow for a better comparison between studies and treatment
modalities. In addition, body position should be considered more
systematically.
Limitations
Our systematic review has several limitations. First, it is limited
by the number of the retrieved studies. Second, the design of the
studies was heterogeneous and given the high rate of case reports,
conclusions must be drawn with caution. This also precluded us
from performing a meta-analysis on prevalence, risk factors and
compare treatment modalities in more detail. We tried to draw
additional information from larger trials on treatment alterna-
tives, but details on remaining respiratory events was usually too
scarce, as the authors often referred to AHI only and subclassifi-
cation of apnea or hypopnea types were missing. Also, after the
diagnosis of TECSA, not all authors systematically searched for
potential other underlying disease or treatment that could explain
the CSA. We therefore could not assess thoroughly, if all cases met
the definition of TECSA. Lastly, we cannot rule out that the slight
increase of central events reported in the patients with TECSA
might be due to night-to-night variability of CSA measurements,
or to underestimation of pre-existing CSA due to different scoring
methodologies, interscorer reliability or change in the sleep study
signal quality.
Conclusion
Although probably rare, TECSA may occur with almost all
alternative treatments for OSAmanagement and not onlywith PAP-
therapies. Since TECSA may be asymptomatic, follow-up studies
should be performed more systematically after non-PAP initiation,
within two to three months after initiation of a non-PAP device and
six months after surgery. Clinicians should be aware of this rare
phenomenon, its potential spontaneous resolution, but also be able
to identify other pathophysiological traits such as cardiac comor-
bidities or medication that will need their intervention. Future
studies are needed to elucidate the true prevalence, severity and
clinical significance of this phenomenon.9
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